BioAtla IPO Presentation Deck

BioAtla's Butterfly CAB Bispecific Platform (CAB)*-TAA CAB-CD3 Higher safety, longer T1/2 simple manufacturing CABS have potential to reduce systemic activation for greater safety and efficacy A Reduced cytokine release syndrome and neurological toxicity Note: "Optional CAB directed against the tumor associated antigen (TAA) Tumor cell (CAB)*-TAA CAB-CD3 T cell Enables T cell engaging therapies with high potency while limiting T cell exhaustion bicatla Four active bispecific programs (BA3182, BA3142, EGFR, Nectin-4) 25

View entire presentation